Why Are Teva Pharmaceutical Shares Trading Higher Today?

Teva Pharmaceutical Industries Ltd's TEVA Q4 sales reached $4.1 billion, shrinking 8% Y/Y, missing the consensus of $4.29 billion. 

  • The decrease is mainly due to lower revenues from generic products in North America and COPAXONE, partially offset by higher revenues from AUSTEDO and AJOVY. 
  • Revenues continued to be affected by the ongoing impact of the COVID-19 pandemic on markets and customer stocking and purchasing patterns.
  • The adjusted gross margin was 56.1% compared to 52.3% a year ago. Adjusted operating income increased 9% to $1.25 billion. 
  • Adjusted EBITDA increased 8% to $1.37 billion.
  • The company generated cash flow from operating activities of $456 million, with a free cash flow of $716 million.
  • Adjusted EPS of $0.77 surpassed the Wall Street estimate of $0.73.
  • Outlook: Teva anticipates FY22 sales of $15.6 - $16.2 billion, below the consensus of $16.32 billion
  • It expects adjusted EPS of $2.40 - $2.60, below the analysts' estimate of $2.64.
  • Free cash flow is expected to be $1.9 billion - $2.2 billion.
  • Teva Pharmaceuticals CEO Schultz said he is optimistic the company can still reach nationwide settlements on Opioid cases in the next 12 months.
  • Price Action: TEVA shares are up 12.20% at $9.31 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsGuidanceHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!